-
公开(公告)号:US20240417476A1
公开(公告)日:2024-12-19
申请号:US18703912
申请日:2022-10-27
Applicant: aTyr Pharma, Inc.
Inventor: Luke G. BURMAN , Yeeting CHONG , Kaitlyn RAUCH , Leslie A. NANGLE
IPC: C07K16/28
Abstract: Provided are antibodies and antigen-binding fragments thereof that preferentially or selectively bind to human neuropilin-2a (NRP2a) variant 1 (v1) and/or variant 2 (v2), relative to other NRP2a isoforms or NRP2b isoforms, and which modulate binding interactions between NRP2a v1/v2 ligands and downstream signaling events. Also included are related therapeutic compositions and methods for treating diseases such as cancers and inflammatory and autoimmune diseases.
-
公开(公告)号:US20240092917A1
公开(公告)日:2024-03-21
申请号:US18477113
申请日:2023-09-28
Applicant: aTyr Pharma, Inc.
Inventor: Luke BURMAN , Yeeting CHONG , Leslie Ann GREENE , David KING , Zhiwen XU , Ryan Andrew ADAMS
IPC: C07K16/28 , A61K39/395 , A61P35/00 , A61P35/04
CPC classification number: C07K16/2863 , A61K39/3955 , A61P35/00 , A61P35/04 , A61K2039/505
Abstract: Provided are affinity matured and humanized antibodies and antigen-binding fragments thereof that specifically bind to human neuropilin-2 (NRP2) polypeptides, including those that modulate binding interactions between human NRP2 and at least one NRP2 ligand, and which thereby modulate subsequent NRP2-mediated downstream signaling events, including related therapeutic compositions and methods for modulating NRP2 activity and treating diseases such as NRP2-associated diseases.
-
公开(公告)号:US20210163606A1
公开(公告)日:2021-06-03
申请号:US17062100
申请日:2020-10-02
Applicant: aTyr Pharma, Inc.
Inventor: Luke BURMAN , Yeeting CHONG , Leslie Ann GREENE , David KING , Zhiwen XU , Ryan Andrew ADAMS
IPC: C07K16/28 , A61K33/243 , A61K39/395 , A61P35/00 , A61P35/04 , A61K31/513
Abstract: Provided are affinity matured and humanized antibodies and antigen-binding fragments thereof that specifically bind to human neuropilin-2 (NRP2) polypeptides, including those that modulate binding interactions between human NRP2 and at least one NRP2 ligand, and which thereby modulate subsequent NRP2-mediated downstream signaling events, including related therapeutic compositions and methods for modulating NRP2 activity and treating diseases such as NRP2-associated diseases.
-
-